“additional milestones include expected updates later this year about our COVID/flu combination vaccine, marstacimab, for hemophilia A and B, and ponsegromab, for Cachexia, a wasting disorder associated with chronic disease.”

In context

“ile strategically addressing the persistent medical need across invasive disease, antibiotic resistance and challenging serotypes. In RSV with Abrysvo, I am pleased to report that yesterday we received an approval for Abrysvo's Act-O-Vial presentation in the United States, a presentation which offers advantages such as a never-frozen, unique system enabling one-step reconstitution highly valued by pharmacists. Additionally, we have submitted for label expansion in both the United States and Europe for adults 18 to 59. In our malignant hematology programs, we are also driving progress. Last week, we reported positive results from a Phase 3 study demonstrating the safety and efficacy of our one-time gene therapy candidate for people with hemophilia A. As we continue to advance our pipeline, additional milestones include expected updates later this year about our COVID/flu combination vaccine, marstacimab, for hemophilia A and B, and ponsegromab, for Cachexia, a wasting disorder associated with chronic disease. Now I’ll turn to our strength with commercial execution of our business. Another strategic area of focus is protecting and growing our core product portfolios while we also maximize the performance of our new products. We continue to see encouraging progress with our team's execution. Nurtec is an example where we are rising to meet substantial demand. This product delivered strong results in the quarter with 44% year-over-year global operational revenue growth. We see additional opportunities for expanding share in both acute and prevention usage, as well as growth opportunities in international markets where we are making progress with our launches. I hope Alexandre will be able to touch based on this during the Q&A Session. Now, I will touch on a few additional product portfolio highli”